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Abstract
Background: Cancer of the ovary is mostly discovered at a late stage and cannot be removed by surgery alone.
Therefore surgery is usually followed by adjuvant chemotherapy. However, few reliable biomarkers exist to predict
response to chemotherapy of ovarian cancer. Previously, we could demonstrate that IL-17 density is indicative for
chemosensitivity. This study focuses on the predictive value of myeloperoxidase (MPO) concerning response to
chemotherapy of ovarian cancer.
Methods: Biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were
stained with MPO after fixation in formalin and embedding in paraffin. For this staining the technique of tissue-
microarray was used. Recurrence within 6 months of the completion of platinum-based chemotherapy was defined
as chemoresistance as previously publised. Data for MPO could be analyzed in 92 biopsies.
Results: MPO and IL-17 positive immune cells correlated significantly in biopsies of primary and recurrent
carcinomas (rs = 0.41; p = 0.004 and rs = 0.40; p = 0.007, respectively). MPO expression alone did not predict
response to chemotherapy, but in multivariate cox regression analysis including age, residual disease, number
of chemotherapy cycles, FIGO classification and combined categorized MPO and IL-17 cell densities of primary cancer
biopsies, the combination of both immune markers was an independent prognostic factor for recurrence-free survival
(p = 0.013, HR = .23, 95CI = 0.07–0.73). There was no chemoresistant patient in the subgroup of MPO + IL-17+, neither in
primary nor in recurrent cancer biopsies.
Conclusions: High MPO positive cell density enhances the indicative value of IL-17 for response to chemotherapy in
ovarian carcinoma. Although, these results have to be validated in a larger cohort.
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Background
Ovarian cancer has an incidence range of 5-15/100’000 in
Europe [1–3]. It is only the 5th most common female can-
cer, but even though it is the most lethal of all female geni-
tal carcinomas. It is mostly discovered at a late stage and
cannot be removed by surgery alone due to late and
unspecific symptoms. Surgical debulking is usually followed
by adjuvant platinum-based chemotherapy. However, most
patients recur with chemoresistant disease.
It is known that tumor microenvironment influences
tumor biology and that tumor behavior is affected by the
immunological environment. According to several previ-
ous publications tumor microenvironment seems to
have significant impact on survival and tumor growth
[4–8]. Tumor-infiltrating lymphocytes (TILs) are fre-
quently thought to mirror tumor immune response to
invasive neoplasms [9]. They were discovered in differ-
ent solid tumors [10, 11]. Indeed, in colorectal cancer
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(CRC) the “immune contexture” [12], especially cells of
the adaptive immune response, are more important con-
cerning prognosis than the TNM staging and might help
in decision making for personalized treatment [13, 14].
There are several previous studies that analyzed different
markers predicting response to platinum-based chemo-
therapy in ovarian cancer with the scope to optimize ad-
juvant treatment [15–17]. However, only few markers
were helpful.
On one side it is known that FOXP3 positive regulatory
T (Treg) cell infiltration is associated with decreased
survival in ovarian cancer [17–19]. On the other side, gran-
ulocytes have largely been neglected by tumor immunolo-
gists [20]. Challenging this, recent studies implied that
neutrophil granulocytes might play an important role in the
prevention of cancer metastasis [21]. Finally, neutrophil
granulocytes are thought to have the capacity to undergo
differentiation into N1 and N2 cells with anti- and pro-
tumor properties, respectively [22, 23]. Therefore tumor in-
filtrating granulocytes regain attention in research [24–26].
In a previous study we could demonstrate that IL-17,
but not FOXP3 positive immune cell infiltration in
primary and recurrent ovarian carcinoma were indicative
of chemosensitivity [27]. Finally it has been shown that
IL-17 can be produced by granulocytes [28, 29] and
other innate immune cells [30] and not only by TILs.
However, in ovarian cancer the role of the innate im-
mune system has not been evaluated to the same extent
as the role of the adaptive immune system. In early stage
lung cancer granulocytes have recently been shown to
stimulate T cell responses in humans [31].
Neutrophilic granulocytes (NG) accumulate myeloper-
oxidase (MPO) in high amounts during their early mat-
uration phase [32]. MPO produces hypochlorous acid
from hydrogen peroxide and chloride anion and is re-
sponsible for the oxidization of tyrosine to tyrosyl radi-
cals. Both are cytotoxic to a variety of microorganisms.
After activation of granulocytes this enzyme is also im-
plicated in the induction of apoptosis [33, 34].
There are few studies reporting the prognostic and
predictive role of MPO in ovarian cancer. Therefore, we
investigated its predictive value for chemosensitivity
alone and in combination with IL-17 expression in a
well characterized cohort of primary ovarian carcinomas
and their matched recurrences which has also been used
for previous publications of our group [35–38].
Methods
Patients
Tissues from ovarian serous carcinomas and their recur-
rences were available at the Pathology Biobank at Path-
ology of the University Hospital of Basel and the Cantonal
Hospitals of Baden, Liestal and St. Gallen, Switzerland.
Mostly high-grade ovarian carcinomas (5.7 % FIGO stage
II, 84.3 % FIGO stage III and 4.3 % FIGO stage IV) were
included in this study after typing according to previous
publications [39, 40]. The tissue microarray (TMA) was
available from previous studies [35–38]. All patients had
recurrences after initial surgery and had received at least
three cycles of platinum-based adjuvant chemotherapy.
The collection was divided into two groups according to re-
sponse to chemotherapy. Recurrence occurring within
6 months after completion of platinum-based chemother-
apy was defined as resistance [41]. The TMA allows investi-
gation of tissues from ovarian carcinomas and matched
recurrences from the same patients as previously shown
[35–38]. The statement concerning the clinical data collec-
tion and ethical considerations can be found in previous
publications [27, 35–38].
Tissue microarray construction
The construction of the tissue microarray has been pre-
viously described [27, 42].
Immunohistochemistry (IHC) and visual analysis
Standard indirect immunoperoxidase procedures (ABC-
Elite, Vectra Laboratories) were used for immunohisto-
chemistry. For MPO staining the following antibody was
used: clone 59A5 Novocastra, Newcastle, UK. In each
tissue spot positive stained tumor immune cell infiltra-
tion (TICI) in the stroma was counted, representing ap-
proximately one high-power-field (10×), intravascular
cells were excluded from analysis (Fig. 1a and b). Two
independent experienced observers (RM and GS) ana-
lyzed the staining for specificity and the amount of TICI
as described above. Cut-off was 22 positive cells/punch
for MPO. Conclusive data for MPO were available in 47
biopsies of primary and 45 biopsies of matched recur-
rent carcinomas, respectively.
Statistical analysis section
Cut-off scores used to classify ovarian carcinomas with low
or high MPO infiltration were obtained by regression tree
analysis, evaluating the best threshold in order to predict
patients’ survival status, on all tumor samples [43]. Specific
scores were set at 22 positive cells/punch. IL-17 data were
available from a previous publication [27]. Kruskal Wallis,
Chi-Square or Fisher’s Exact tests were used for the
association of the clinicopathological features with the
corresponding four groups of the biomarkers. Univariate
recurrence-free and overall survival analysis was carried
out by the Kaplan-Meier method and log rank test.
The assumption of proportional hazards was verified for
both markers by analyzing the correlation of Schoenfeld
residuals and the ranks of individual failure times. Any
missing clinicopathological information was assumed to
be missing at random. Subsequently, a multivariate Cox
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regression analysis was performed including MPO and
IL-17. The hazard ratios (HR) and the 95 % confidence
intervals (CI) were used to determine prognostic effects
on survival time. Spearman’s rank correlation was used
to analyze the correlation between MPO and IL-17. All
statistical analyses were made using STATA software
version 13 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
The baseline characteristics of the patient cohort have been
described previously [27] (Table 1). Briefly recurrence-free
(RFS) and overall survival (OS) in the chemoresistant
Table 1 Patient characteristics (n = 47)a
n (%)









<2 cm 17 (36.2)
>2 cm 13 (27.7)
Numbers of chemotherapy cycles
<6 7 (14.9)
6 or more 39 (83.0)
CSb 33 (70.2)
CRb 14 (29.8)
RFSc (mean/SE) 10.1 (1.4)
OSc (mean/SE) 41.4 (4.3)
amissing clinicopathological information was assumed to be missing at random
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival
Fig. 1 MPO and corresponding IL-17 specific staining in high grade ovarian carcinoma. Tumor punches are representative of low (panel a) and
high (panel b) density of MPO positive TICI. Panel c shows an IL-17 specific staining in a section from the same biopsy shown in b. Magnification: 10×
Table 2 Patients’ characteristics according to dichotomized
distribution of MPO in the overall cohort (n = 47)a
MPO high MPO low p-value
n = 12 (100 %) n = 35 (100 %)
Age (median, range) 55 (45–73) 60 (34–77) 0.196
FIGO stage
II 0 1 (2.9) 0.401
IIIA 0 1 (2.9)
IIIB 3 (25.0) 2 (5.7)
IIIC 7 (58.3) 25 (71.4)
IV 2 (16.7) 6 (17.1)
Residual disease
None 4 (33.3) 12 (34.3) 0.919
<2 cm 5 (41.7) 12 (34.3)
>2 cm 3 (25.0) 10 (28.6)
Numbers of chemotherapy cycles
<6 1 (8.3) 6 (17.1) 0.440
6 or more 11 (91.7) 28 (80.0)
Primary cancer biopsies
CSb 10 (83.3) 23 (65.7) 0.249
CRb 2 (16.7) 12 (34.3)
Recurrent cancer biopsies (n = 10/35)
CSb 9 (90.0) 23 (65.7) 0.135
CRb 1 (10.0) 12 (34.3)
RFSc (mean/SE) 11.9 (2.7) 9.5 (1.6) 0.380
OSc (mean/SE) 56.8 (14.4) 39.3 (4.4) 0.139
apercentages may not add to 100 % due to missing values of defined
variables, missing clinicopathological information was assumed to be missing
at random. Variables are indicated as absolute numbers, %, median or range.
Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage,
residual disease, numbers of chemotherapy cycles and chemoresistance were
analyzed using the Chi-Square or the Fisher’s Exact test
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival
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Fig. 2 a Kaplan Meier survival curve of recurrence-free survival according to MPO and IL-17 density in primary cancer biopsies. Impact of MPO+
and IL-17+ tumor infiltrating immune cells on recurrence-free survival in patients with high grade ovarian carcinoma. Kaplan-Meier recurrence-
free survival curves were split according to MPO+ and IL-17+ cell density in patients bearing high grade ovarian carcinoma as indicated. Cut-off
values established by regression tree analysis were 22 cells/punch for MPO and 1 cell/punch for IL-17 cell infiltration. Cumulative effects of tumor
infiltration by MPO+ and IL-17+ cells were explored. Blue line indicates to tumors with low MPO+ and low IL-17+ cell infiltration. Green line refers
to tumors with high IL-17+ cell infiltration. Red line refers to tumors with high MPO+ cell infiltration and yellow line refers to tumors with high
MPO+ and high IL-17+ cell infiltration. b Kaplan Meier survival curve of overall survival according to MPO and IL-17 density in primary cancer
biopsies. Impact of MPO+ and IL-17+ tumor infiltrating immune cells on overall survival in patients with high grade ovarian carcinoma. Kaplan-
Meier overall survival curves were split according to MPO+ and IL-17+ cell density in patients bearing high grade ovarian carcinoma as indicated.
Cut-off values established by regression tree analysis were 22 cells/punch for MPO and 1 cell/punch for IL-17 cell infiltration. Cumulative effects of
tumor infiltration by MPO+ and IL-17+ cells were explored. Blue line indicates to tumors with low MPO+ and low IL-17+ cell infiltration. Green
line refers to tumors with high IL-17+ cell infiltration. Red line refers to tumors with high MPO+ cell infiltration and yellow line refers to tumors
with high MPO+ and high IL-17+ cell infiltration
Table 3 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch
for IL-17 [27] in primary carcinomas (n = 47)a
MPO-/IL17-
n = 21 (100 %)
MPO+/IL17-
n = 8 (100 %)
MPO-/IL17+
n = 12 (100 %)
MPO+/IL17+
n = 6 (100 %)
p-value
Age (median, range) 62 (39–77) 59.5 (50–65) 57 (34–72) 55 (45–73) 0.742
FIGO stage
II 0 0 1 (8.3) 0 0.029
IIIA 1 (4.7) 0 0 0
IIIB 2 (9.5) 0 0 3 (50.0)
IIIC 17 (81.1) 5 (62.5) 8 (66.7) 2 (33.3)
IV 1 (4.7) 3 (37.5) 3 (25.0) 1 (16.7)
Residual disease
None 9 (42.9) 2 (25.0) 3 (25.0) 2 (33.3) 0.262
<2 cm 6 (28.6) 1 (12.5) 7 (58.3) 3 (50.0)
>2 cm 5 (23.8) 5 (62.5) 2 (16.7) 1 (16.7)
Numbers of chemotherapy cycles
<6 5 (23.8) 0 1 (8.3) 1 (16.7) 0.412
6 or more 15 (71.4) 8 (100.0) 11 (91.7) 5 (83.3)
CSb 14 (66.7) 2 (25.0) 11 (91.7) 6 (100.0) 0.004
CRb 7 (33.3) 6 (75.0) 1 (8.3) 0
RFSc (mean/SE) 8.1 (1.7) 3.9 (1.6) 14.9 (3.3) 16 (3.9) 0.024
OSc (mean/SE) 36 (4.5) 33.4 (9.6) 52.4 (12.1) 72 (15.0) 0.113
Bold data statistically significant p < 0.05
apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random.
Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease,
numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival
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group was significantly shorter than in the chemosensitive
group (2.2 ± 0.3 vs 18.2 ± 2.0 months, p < 0.0001 and 27 ±
5.3 vs. 49.6 ± 4.0 months, p = 0.0003, respectively). The
analysis by MPO density is summarized in Table 2.
MPO positive immune cell infiltration in paired primary
and recurrent ovarian carcinoma
Mean number of infiltrating MPO positive cells in pri-
mary and recurrent cancer biopsies were 16.6 (±21.6)
and 19.0 (±34.8), respectively. Neither for dichotomized
MPO density in primary, nor in recurrent cancer biop-
sies a significant association with any clinicopathological
feature was found (Table 2). Twelve out of 47 and 10
out of 45 displayed a high MPO cell density in primary
and recurrent cancer biopsies, respectively. Finally, MPO
density in primary and recurrent cancer biopsies did not
show any significant association with chemosensitivity
(p = 0.249 and p = 0.135) or any other clinicopathological
feature (Table 2).
Correlation analysis of MPO and IL-17 positive tumor
immune cell infiltration
For more information concerning the relationship of
MPO and IL-17 positive cell infiltration a correlation
analysis of both markers was performed. Interestingly
MPO and IL-17 positive TICI correlated significantly in
all biopsies (rs = 0.42; p < 0.001), in biopsies of only pri-
mary (rs = 0.41; p = 0.004) and in biopsies of only recur-
rent carcinomas (rs = 0.40; p = 0.007).
Combined analysis of MPO and IL-17 positive cell density
Based on the correlation analysis results, a combined
analysis of MPO and IL-17 cell density was performed.
As shown in Fig. 2a, MPO and IL-17 positive TICI fre-
quency was significantly associated with a longer RFS in
biopsies of primary cancers (n = 47, p = 0.011), although
the combined marker analysis did not show significant
association with OS (Fig. 2b, p = 0.283). In addition,
there was a significant association with chemosensitivity
(p = 0.004) and FIGO classification (p = 0.029) in primary
cancer biopsies (Tables 3 and 4).
In biopsies from carcinoma recurrences, no significant
association with RFS could be found (p = 0.121).
Multivariate analysis of synergistic effect
In a multivariate cox regression analysis including age,
residual disease, FIGO classification, number of chemo-
therapy cycles and categorized MPO and IL-17 cell
Table 4 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch
for IL-17 [27] in recurrent carcinomas (n = 45)a
MPO-/IL17-
n = 23 (100 %)
MPO+/IL17-
n = 4 (100 %)
MPO-/IL17+
n = 12 (100 %)
MPO+/IL17+
n = 6 (100 %)
p-value
Age (median, range) 62 (47–77) 59.5 (45–69) 59 (34–68) 54.5 (39–60) 0.277
FIGO stage
II 0 0 1 (8.3) 0 0.574
IIIA 0 0 1 (8.3) 0
IIIB 2 (8.7) 0 2 (16.7) 1 (16.7)
IIIC 17 (73.9) 4 (100.0) 6 (50.0) 3 (50.0)
IV 4 (17.4) 0 2 (16.7) 2 (33.3)
Residual disease
None 7 (30.4) 0 6 (50.0) 2 (33.3) 0.046
<2 cm 5 (21.7) 3 (66.7) 5 (41.7) 4 (66.7)
>2 cm 10 (43.5) 1 (33.3) 1 (8.3) 0
Numbers of chemotherapy cycles
<6 3 (13.0) 0 3 (25.0) 1 (16.7) 0.806
6 or more 19 (82.6) 4 (100.0) 9 (75.0) 5 (83.3)
CSb 13 (56.5) 3 (66.7) 10 (83.3) 6 (100.0) 0.123
CRb 10 (43.5) 1 (33.3) 2 (16.7) 0
RFSc (mean/SE) 7.7 (1.8) 12.5 (7.1) 14.2 (2.5) 8.3 (2.2) 0.121
OSc (mean/SE) 33.5 (5.8) 20 (2.0) 53.4 (9.3) 45.2 (6.5) 0.074
Bold data statistically significant p < 0.05
apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random.
Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease,
numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival
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density, the combination of the immune markers was an
independent prognostic factor for RFS in primary cancer
biopsies (Table 5).
Discussion
As in ovarian carcinoma, surgical tumor debulking is
often followed by adjuvant platinum-based chemotherapy
it would be helpful to find predictive markers for chemor-
esponse. Based on such biomarkers it would be possible
to carry out extended chemotherapy regimen and repeti-
tive surgical procedures. In our previous studies we identi-
fied different potential therapeutical targets and IL-17 as
predictive marker for chemosensitivity [27, 35–38]. As
previously mentioned there is a resurgent interest in the
scientific community concerning the role of granulocytes
in tumor immunology [22, 24, 31]. Indeed, they have usu-
ally been associated with poor prognosis [20]. But experi-
mental models in the past have proposed an anti-tumor
role through the activation of T cells [44, 45]. Furthermore
recently, granulocyte polarization has been described [22]
and the ability of granulocytes to promote lymphocyte ac-
tivation in the tumor environment has been reported [31].
The composition of tumor microenvironment has been
shown to significantly impact tumor progression and clin-
ical outcome [12]. Similar to a variety of cancers of differ-
ent origins, T lymphocyte infiltration in ovarian cancer
has a positive prognostic role [46]. Most interestingly,
ovarian cancer infiltration by IL-17 producing cells has
been found to be associated with either longer RFS or
good prognosis by us and others [27, 47]. However, there
is no evidence concerning the potential clinical relevance
of granulocyte infiltration in ovarian cancer.
In our previous study we found that IL-17 positive
TICI were significantly more frequent in the chemosen-
sitive ovarian carcinoma group [27]. Granulocytes and
other immune cells of the innate immune system can
produce IL-17 [28–30]. On the other hand, TNF-alpha
in the tumor microenvironment could attract myeloid
cells in an IL-17-dependent manner and contribute to
tumor-promotion [48]. Therefore we investigated the
predictive role of MPO, an enzyme that is expressed in
myeloid cells, alone and together with IL-17. Finally we
found that the combination of both markers was an in-
dependent prognostic factor for RFS. However, in this
study IL-17 was the dominant marker for prediction of
RFS. A further limitation is the small sample size. There-
fore, our results have to be validated in an independent
larger patient cohort.
Conclusion
Based on the results in this study, we conclude that the
combination of high MPO positive cell density and IL-17
expression enhances the indicative value for the response
of ovarian carcinomas to chemotherapy, as it in addition
has prognostic value regarding recurrence-free survival in
ovarian carcinoma. Although, these results have to be vali-
dated in a larger cohort.
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